Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline

This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.

Study Overview

• Status: Completed
• Conditions: Alzheimer's Disease
• Intervention / Treatment: Drug: florbetapir (18F)

• Study Type: Interventional
• Enrollment (Actual): 641
• Phase: Phase 4

Contacts and Locations

Study Locations

• France
  • Amiens, France, 80054
    • Research Site
  • Bordeaux, France, 33076
    • Research Site
  • Bron, France, 69500
    • Research Site
  • Dijon, France, 21033
    • Research Site
  • Lille, France, 59037
    • Research Site
  • Marseille, France, 13385
    • Research Site
  • Montpellier, France, 34000
    • Research Site
  • Nancy, France, 54035
    • Research Site
  • Nantes, France, 44093
    • Research Site
  • Nice, France, 06003
    • Research Site
  • Paris, France, 75651
    • Research Site
  • Pessac, France, 33604
    • Research Site
  • Reims, France, 51092
    • Research Site
  • Rouen, France, 76031
    • Research Site
  • Strasbourg, France, 67098
    • Research Site
  • Toulouse, France, 31059
    • Research Site
  • Tours, France, 37044
    • Research Site
  • Villeurbanne, France, 69100
    • Research Site
• Italy
  • Bergamo, Italy, 24127
    • Research Site
  • Brescia, Italy, 25123
    • Research Site
  • Brescia, Italy, 20125
    • Research Site
  • Florence, Italy, 50139
    • Research Site
  • Genoa, Italy, 16128
    • Research Site
  • Genoa, Italy, 16132
    • Research Site
  • Milan, Italy, 20162
    • Research Site
  • Milan, Italy, 20122
    • Research Site
  • Milan, Italy, 20132
    • Research Site
  • Milan, Italy, 20133
    • Research Site
  • Modena, Italy, 41126
    • Research Site
  • Monza, Italy, 20900
    • Research Site
  • Padova, Italy, 35128
    • Research Site
  • Parma, Italy, 43100
    • Research Site
  • Perugia, Italy, 06132
    • Research Site
  • Pisa, Italy, 56126
    • Research Site
  • Rome, Italy, 00133
    • Research Site
  • Rome, Italy, 00179
    • Research Site
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85054
      • Research Site
    • Phoenix, Arizona, United States, 85006
      • Research Site
    • Scottsdale, Arizona, United States, 85258
      • Research Site
    • Sun City, Arizona, United States, 85351
      • Research Site
  • Florida
    • Clearwater, Florida, United States, 33756
      • Research Site
    • Miami Beach, Florida, United States, 33140
      • Research Site
    • Orlando, Florida, United States, 32806
      • Research Site
    • West Palm Beach, Florida, United States, 33407
      • Research Site
  • Louisiana
    • Shreveport, Louisiana, United States, 71130
      • Research Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Research Site
    • Chestnut Hill, Massachusetts, United States, 02467
      • Research Site
    • Quincy, Massachusetts, United States, 02169
      • Research Site
  • Nevada
    • Las Vegas, Nevada, United States, 89106
      • Research Site
    • Las Vegas, Nevada, United States, 89128
      • Research Site
  • New York
    • Patchogue, New York, United States, 11772
      • Research Site
  • North Carolina
    • Durham, North Carolina, United States, 27710
      • Research Site
    • Greensboro, North Carolina, United States, 27405
      • Research Site
  • Rhode Island
    • Providence, Rhode Island, United States, 02903
      • Research Site
    • Providence, Rhode Island, United States, 02906
      • Research Site
  • Utah
    • Salt Lake City, Utah, United States, 84108
      • Research Site
  • Vermont
    • Bennington, Vermont, United States, 05201
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years to 90 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Patients may be enrolled in the mild impairment (not demented) group if the following criteria are met:

1. Males or females ≥ 50 to <= 90 years of age.
2. Have cognitive decline verified by a study partner or cognitive impairment verified by the study physician.
3. Have a study partner who provides separate consent and is willing to accompany the patient on all of the study visits.
4. Have an MMSE score of 24 to 30 inclusive.
5. Can tolerate a 10-minute PET scan.
6. Have the ability to cooperate and comply with all study procedures.
7. Have an enrolling physician who has less than high confidence in their diagnosis for the patient related to the cognitive decline at the time of enrollment.
8. Ability to provide informed consent for study procedures.

Patients may be enrolled in the dementia group if the following criteria are met:

1. Are males or females ≥ 50 to <= 90 years of age.
2. Meet clinical criteria for dementia.
3. Have a caregiver who provides separate consent and is willing to accompany the patient on all of the study visits.
4. Have an MMSE score of 16 to 24 inclusive.
5. Have not received a clinical examination and/or laboratory test results that strongly indicates a non-neurodegenerative cause for the patients cognitive impairment.
6. Can tolerate a 10-minute PET scan.
7. Have the ability to cooperate and comply with all study procedures.
8. Have an enrolling physician who has less than high confidence in their diagnosis for the patient related to the cognitive decline at the time of enrollment.
9. Ability to provide informed consent for study procedures. (If the patient is incapable of giving informed consent, the patient's legal representative may consent on behalf of the patient but the patient must still confirm assent. This person may serve as the study partner as well).

Exclusion Criteria:

Patients will be excluded from enrollment if they:

1. Have a current serious or unstable illness;
2. The patient or enrolling physician knows the result of a previous amyloid imaging scan;
3. The patient has a known brain lesion, pathology or alternative diagnosis that strongly explains the patient's clinical presentation;
4. Are receiving any investigational medications, or have participated in a trial with investigational medications within the last 30 days;
5. Have ever participated in an experimental study with an amyloid targeting agent (e.g. anti-amyloid immunotherapy, γ -secretase or β -secretase inhibitor) unless it can be documented that the patient received only placebo during the course of the trial;
6. Have had a radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session; or
7. Are females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception.

Patients will also be excluded from enrollment if their enrolling physician:

1. Does not consider Alzheimer's disease as a potential cause of the patient's cognitive decline.
2. Is not the primary physician taking care of the patient with respect to the management of their cognitive impairment.
3. Cannot categorize the patient as either: a) having a documented and completed evaluation for cognitive decline within the past 18 months old; or b) currently undergoing evaluation for cognitive decline.
4. Is unwilling to suspend all testing and other evaluation procedures between the time of the baseline evaluation of the enrolling physician's diagnosis and management plan and the time the completion of the PET scan.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention; Subjects will receive florbetapir (18F) PET scans and physicians will have immediate access to PET scan results.	Drug: florbetapir (18F); Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration; Other Names: Amyvid; 18F-AV-45; florbetapir F 18; AV-45
Experimental: Control; Subjects will receive florbetapir (18F) PET scans but physicians will be blinded to PET scan results for 12 months	Drug: florbetapir (18F); Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration; Other Names: Amyvid; 18F-AV-45; florbetapir F 18; AV-45

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical and Diagnostic Change in Patient Management	Comparison of the percentage of patients who have a change in management from baseline to 3 months for patients who receive scan results immediately (intervention arm) and those who receive scan results 12 months later (control arm).	Baseline and 3 months
Change in ADAS-Cog 11 Total Score	Change from baseline in the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) 11 Score in patients with mild impairment by positive or negative florbetapir (18F) PET scan result (Aß+/Aß-). ADAS-Cog scores (range 0-70) indicate performance on a series of 11 cognitive tasks where 0 indicates the highest level of cognitive performance and 70 indicates the lowest level of cognitive performance. Change in ADAS-Cog scores were calculated by subtracting the baseline score from the 12 month score. A change in ADAS-Cog greater than 0 indicates a deterioration in cognitive performance whereas a change in ADAS-Cog less than 0 indicates improved cognitive performance.	Baseline and 12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Patient's Clinical Diagnosis	Comparison of the percentage of patients who have a change in diagnosis from baseline to 3 months for patients in the intervention and control arms for whom the scan result was not predicted by the initial diagnosis.	Baseline and 3 months
Change in Diagnostic Confidence	Comparison of the percentage point change in the physician's diagnostic confidence from baseline to month 3 in the intervention and control arms for patients whose scan result was predicted by their baseline clinical diagnosis. Diagnostic confidence was recorded by the physician as a whole number percent from 0-100% and the change in confidence was calculated by subtracting the baseline confidence from the confidence recorded at the specified timepoint. Values greater than zero reflect increased diagnostic confidence; values less than zero reflect decreased diagnostic confidence.	Baseline and 3 months
Change in Patient Management: Advice/Counseling	Comparison of the percentage of patients in the intervention and control arms who have a change in management relating to advice and counseling from baseline to 3 months.	Baseline and 3 months
Change in Caregiver Self-efficacy	Comparison of the change in self-efficacy between intervention and control arms. Change in self-efficacy is defined as the difference between total score on the Fortinsky: Family caregivers' self-efficacy for managing dementia scale at Follow-up (3 months) and baseline. Self-efficacy for managing dementia is defined in terms of specific behaviors or tasks that can be learned, and that are highly relevant to daily management of the disease process. The scale consists of 10 questions, each with responses ranging from 1 (not at all certain) to 10 (very certain). The total score is calculated by summing the response for each item. The total score ranges from 10 to 100, with increasing scores representing increasing caregiver self-efficacy.	Baseline and 3 months
Change in Patient Management: Individual Categories	Compare the percentage of patients with a change from baseline in the individual patient management categories at 3 months in the interventional and control arms.The individual categories are: Major diagnostic tests, Alzheimer's/cognition medication, neuropsychological tests, physician follow-up for re-evaluation or specialist referral.	Baseline and 3 months

Collaborators and Investigators

• Sponsor: Avid Radiopharmaceuticals
• Collaborators: Eli Lilly and Company

Study record dates

Study Major Dates

• Study Start: October 1, 2012
• Primary Completion (Actual): April 1, 2015
• Study Completion (Actual): April 1, 2015

Study Registration Dates

• First Submitted: October 5, 2012
• First Submitted That Met QC Criteria: October 9, 2012
• First Posted (Estimate): October 10, 2012

Study Record Updates

• Last Update Posted (Estimate): August 17, 2016
• Last Update Submitted That Met QC Criteria: July 8, 2016
• Last Verified: July 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Neurodegenerative Diseases; Dementia; Tauopathies; Cognition Disorders; Alzheimer Disease; Cognitive Dysfunction
• Other Study ID Numbers: 18F-AV-45-A18